363 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
)
(A) ImmunoGen will remain an independent public company, (B) the Company Common Stock will continue to be listed and traded on Nasdaq and registered … will not receive any payment for their shares of Company Common Stock. Instead, ImmunoGen will remain an independent public company, the Company Common Stock
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
an independent public company, (B) the Company Common Stock will continue to be listed and traded on Nasdaq and registered under the Exchange Act, and (C … Stock. Instead, ImmunoGen will remain an independent public company, the Company Common Stock will continue to be listed and traded on Nasdaq
DEFA14A
IMGN
Immunogen, Inc.
21 Dec 23
Additional proxy soliciting materials
3:54pm
?
Nothing changes at this time. ImmunoGen continues to operate as an independent public company until the closing of the transaction.
Who approached whom … of the transaction. ImmunoGen continues to operate as an independent public company until the closing of the transaction.
Will there be a job for me
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
or owing to any employee, independent contractor, creditor, shareholder or other Person, and (iii) neither the Company nor any of its Subsidiaries has … of the Company or any temporary agency employee, consultant or other independent contractor of the Company or any Company Subsidiary, other than travel, business
8-K
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
or owing to any employee, independent contractor, creditor, shareholder or other Person, and (iii) neither the Company nor any of its Subsidiaries has … of the Company or any temporary agency employee, consultant or other independent contractor of the Company or any Company Subsidiary, other than travel, business
8-K
bxjt4y7tl3lbv9d86
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
EX-5.1
uin2zoc1
5 May 23
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-1.1
7naxecb4mfd090cez29q
5 May 23
Entry into a Material Definitive Agreement
5:15pm
8-K
1zqfl
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
m3y iuckqk
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
jwvrovxksrf ajs
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
zfdd4e n0u1baj
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
S-8
EX-23.1
xcxgy vhz3i
28 Apr 23
Registration of securities for employees
5:13pm
S-8
EX-5.1
iffc92h2a 57zlj
28 Apr 23
Registration of securities for employees
5:13pm
S-8
EX-5.1
hc2tfi
28 Apr 23
Registration of securities for employees
5:10pm
S-8
EX-23.1
g265n2fad5njhtcvyp4
28 Apr 23
Registration of securities for employees
5:10pm
DEFA14A
jl0alucrcj
26 Apr 23
Additional proxy soliciting materials
5:01pm